Serum IgA Subclasses and Molecular Forms in HIV Infection: Selective Increases in Monomer and Apparent Restriction of the Antibody Response to IgA1 Antibodies Mainly Directed at env Glycoproteins

1992 ◽  
Vol 8 (10) ◽  
pp. 1773-1780 ◽  
Author(s):  
PAMELA A. KOZLOWSKI ◽  
SUSAN JACKSON
Gut ◽  
1998 ◽  
Vol 42 (3) ◽  
pp. 357-361 ◽  
Author(s):  
T Schneider ◽  
T Zippel ◽  
W Schmidt ◽  
G Pauli ◽  
U Wahnschaffe ◽  
...  

Background—Secretory immunity is a major defence mechanism against infections at mucosal surfaces which are common in HIV infected patients.Aims—To analyse intestinal immunoglobulin production in HIV infection in comparison with that in saliva and serum.Patients and methods—Immunoglobulin G (IgG), A (IgA), and M (IgM) concentrations were determined in supernatants of short term cultured duodenal biopsy samples, serum, and saliva from HIV infected patients (n = 28) and controls (n = 14) by radial immunodiffusion.Results—IgG was increased in the supernatants of short term cultured biopsy samples and saliva from HIV infected patients compared with controls (p<0.01), but IgA and IgM levels were normal. In contrast, both IgG and IgA concentrations in serum were higher in HIV infected patients than in controls (p<0.002). No correlation was found between IgA produced by duodenal biopsy specimens and serum IgA.Conclusion—Abnormalities in mucosal immunoglobulin production in HIV infection were suprisingly small, indicating that specific secretory immunity rather than quantitative immunoglobulin production may be impaired. However, increased production of IgG could contribute to mucosal inflammation by complement activation. Our findings of normal mucosal IgA production and the lack of correlation between serum and mucosal IgA argues against an intestinal origin for the increased serum IgA levels in HIV infected patients.


1995 ◽  
Vol 171 (1) ◽  
pp. 256-256 ◽  
Author(s):  
L. Favennec ◽  
E. Comby ◽  
J. J. Ballet ◽  
P. Brasseur

1999 ◽  
Vol 45 (2) ◽  
pp. 309-310 ◽  
Author(s):  
Mario Berth ◽  
Joris Delanghe ◽  
Michel Langlois ◽  
Marc De Buyzere

2020 ◽  
Vol 6 (2) ◽  
Author(s):  
SahBandar I ◽  
Terakubo J ◽  
Pattison RJ ◽  
Park E ◽  
Oishi MK ◽  
...  

Background: Human Immunodeficiency Virus (HIV) infection may alter antibody responses against periodontopathic bacteria, increasing the susceptibility for gingival and periodontal disorders in HIV-infected individuals. We describe the oral health of HIV-infected individuals receiving stable Antiretroviral Therapy (ART) and determine their association with serum anti-periodontopathic bacteria antibody level.


2011 ◽  
Vol 10 (1) ◽  
pp. 55 ◽  
Author(s):  
Daniel KM Muema ◽  
Francis M Ndungu ◽  
Samson M Kinyanjui ◽  
James A Berkley

2007 ◽  
Vol 75 (8) ◽  
pp. 3812-3822 ◽  
Author(s):  
Mohamed D. Abd Alla ◽  
Gary L. White ◽  
Tyson B. Rogers ◽  
Max E. Cary ◽  
David W. Carey ◽  
...  

ABSTRACT We designed an amebiasis subunit vaccine that is constructed by using four peptide epitopes of the galactose-inhibitable lectin heavy subunit that were recognized by intestinal secretory immunoglobulin A (IgA) antibodies from immune human subjects. These epitopes are contained in the region encompassing amino acids 758 to 1134 of the lectin heavy subunit, designated LC3. Baboons (Papio anubis) are natural hosts for Entamoeba histolytica; naturally infected baboons raised in captivity possess serum IgA antibodies to the same four LC3 epitopes as humans. Uninfected, seronegative baboons received four intranasal immunizations at 7-day intervals with the synthetic peptide vaccine (400, 800, or 1,600 μg per nostril) with cholera toxin (20 μg) as the adjuvant. As determined by an enzyme-linked immunosorbent assay (ELISA), each dose of the peptide vaccine elicited antipeptide serum IgA and IgG and intestinal IgA antibody responses in all six immunized baboons by day 28, 7 days after the last immunization (P, <0.01 for each dose compared to the cholera toxin control). The peptide vaccine elicited serum IgG and intestinal IgA antibodies that recognized purified recombinant LC3 protein (P, <0.008 and 0.02, respectively) and native lectin protein (P < 0.01). In addition, an indirect immunofluorescence assay with whole trophozoites (P < 0.01) and Western blot analysis confirmed that serum IgG antibodies from vaccinated baboons recognized native lectin protein on the surfaces of axenic E. histolytica trophozoites or from solubilized amebae. All four synthetic peptides were immunogenic; the vaccine elicited dose- and time-dependent responses, as determined by ELISA optical density readings indicating the production of serum and intestinal antibodies (P, <0.02 for antipeptide and antilectin antibodies). As a positive control, intranasal immunization with purified recombinant LC3 protein with cholera toxin as the adjuvant elicited a serum anti-LC3 IgA and IgG antibody response (P, 0.05 and <0.0001, respectively); however, no intestinal anti-LC3 IgA antibody response was observed (P = 0.4). Of interest, serum IgA and IgG antibodies elicited by the recombinant LC3 vaccine did not recognize any of the four putatively protective LC3 peptide epitopes. Both serum and fecal antibodies elicited by the peptide vaccine exhibited neutralizing activity, as determined by their dose-dependent inhibition of the galactose-specific adherence of E. histolytica trophozoites to Chinese hamster ovary cells in vitro (P, <0.001 for each group of antibodies compared to the control). In summary, a lectin-based intranasal polylysine-linked synthetic peptide vaccine was effective in eliciting an adherence-inhibitory, intestinal antilectin IgA antibody response in baboons. Future studies with the baboon model will determine vaccine efficacy against asymptomatic E. histolytica intestinal infection.


2017 ◽  
Vol 91 (17) ◽  
Author(s):  
Gabriel A. Wagner ◽  
Elise Landais ◽  
Gemma Caballero ◽  
Pham Phung ◽  
Sergei L. Kosakovsky Pond ◽  
...  

ABSTRACT Understanding whether the neutralizing antibody (NAb) response impacts HIV-1 superinfection and how superinfection subsequently modulates the NAb response can help clarify correlates of protection from HIV exposures and better delineate pathways of NAb development. We examined associations between the development of NAb and the occurrence of superinfection in a well-characterized, antiretroviral therapy (ART)-naive, primary infection cohort of men who have sex with men. Deep sequencing was applied to blood plasma samples from the cohort to detect cases of superinfection. We compared the NAb activity against autologous and heterologous viruses between 10 participants with intrasubtype B superinfection and 19 monoinfected controls, matched to duration of infection and risk behavior. Three to 6 months after primary infection, individuals who would later become superinfected had significantly weaker NAb activity against tier 1 subtype B viruses (P = 0.003 for SF-162 and P = 0.017 for NL4-3) and marginally against autologous virus (P = 0.054). Lower presuperinfection NAb responses correlated with weaker gp120 binding and lower plasma total IgG titers. Soon after superinfection, the NAb response remained lower, but between 2 and 3 years after primary infection, NAb levels strengthened and reached those of controls. Superinfecting viruses were typically not susceptible to neutralization by presuperinfection plasma. These observations suggest that recently infected individuals with a delayed NAb response against primary infecting and tier 1 subtype B viruses are more susceptible to superinfection. IMPORTANCE Our findings suggest that within the first year after HIV infection, a relatively weak neutralizing antibody response against primary and subtype-specific neutralization-sensitive viruses increases susceptibility to superinfection in the face of repeated exposures. As natural infection progresses, the immune response strengthens significantly in some superinfected individuals. These findings will inform HIV vaccine design by providing testable correlates of protection from initial HIV infection.


2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Ulrike Steffen ◽  
Carolien A. Koeleman ◽  
Maria V. Sokolova ◽  
Holger Bang ◽  
Arnd Kleyer ◽  
...  

AbstractMonomeric serum immunoglobulin A (IgA) can contribute to the development of various autoimmune diseases, but the regulation of serum IgA effector functions is not well defined. Here, we show that the two IgA subclasses (IgA1 and IgA2) differ in their effect on immune cells due to distinct binding and signaling properties. Whereas IgA2 acts pro-inflammatory on neutrophils and macrophages, IgA1 does not have pronounced effects. Moreover, IgA1 and IgA2 have different glycosylation profiles, with IgA1 possessing more sialic acid than IgA2. Removal of sialic acid increases the pro-inflammatory capacity of IgA1, making it comparable to IgA2. Of note, disease-specific autoantibodies in patients with rheumatoid arthritis display a shift toward the pro-inflammatory IgA2 subclass, which is associated with higher disease activity. Taken together, these data demonstrate that IgA effector functions depend on subclass and glycosylation, and that disturbances in subclass balance are associated with autoimmune disease.


1999 ◽  
Vol 67 (5) ◽  
pp. 2218-2224 ◽  
Author(s):  
Lin-Chi Chen ◽  
David L. Goldman ◽  
Tamara L. Doering ◽  
Liise-anne Pirofski ◽  
Arturo Casadevall

ABSTRACT The prevalence and specificity of serum antibodies toCryptococcus neoformans proteins was studied in mice and rats with experimental infection, in individuals with or without a history of potential laboratory exposure to C. neoformans, human immunodeficiency virus (HIV)-positive individuals who developed cryptococcosis, in matched samples from HIV-positive individuals who did not develop cryptococcosis, and in HIV-negative individuals. Rodents had little or no serum antibody reactive with C. neoformans proteins prior to infection. The intensity and specificity of the rodent antibody response were dependent on the species, the mouse strain, and the viability of the inoculum. All humans had serum antibodies reactive with C. neoformans proteins regardless of the potential exposure, the HIV infection status, or the subsequent development of cryptococcosis. Our results indicate (i) a high prevalence of antibodies reactive with C. neoformansproteins in the sera of rodents after cryptococcal infection and in humans with or without HIV infection; (ii) qualitative and quantitative differences in the antibody profiles of HIV-positive individuals; and (iii) similarities and differences between humans, mice, and rats with respect to the specificity of the antibodies reactive with C. neoformans proteins. The results are consistent with the view that C. neoformans infections are common in human populations, and the results have implications for the development of vaccination strategies against cryptococcosis.


Sign in / Sign up

Export Citation Format

Share Document